RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration ("FDA") has denied its most recent application seeking Breakthrough Therapy designation ("BTD") for aviptadil.